Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Wright

Showing results (81-90 of 129) with videos related to

Pageof 13
Sort By:
The American Journal of Gastroenterology|December 24, 2014
Metabolic phenotyping for enhanced mechanistic stratification of chronic hepatitis C-induced liver fibrosisCaroline J Sands, Indra N Guha, Michael Kyriakides, et al.
BMC Nephrology|May 21, 2021
Patient perspectives of target weight management and ultrafiltration in haemodialysis: a multi-center surveyDavid Keane, Megan Glyde, Indranil Dasgupta, et al.
BMJ Open|March 16, 2019
Validated methods to identify patients with asthma-COPD overlap in healthcare databases: a systematic review protocolJoseph Emil Amegadzie, Oluwatosin Badejo, John-Michael Gamble, et al.
International Journal of Molecular Sciences|November 9, 2024
Adjuvanted Modified Bacterial Antigens for Single-Dose VaccinesRoberta Di Benedetto, Luisa Massai, Mark Wright, et al.
Plos One|October 3, 2013
Ascitic microbiota composition is correlated with clinical severity in cirrhosis with portal hypertensionGeraint B Rogers, Christopher J van der Gast, Kenneth D Bruce, et al.
Emerging Infectious Diseases|May 19, 2006
Coccidioidomycosis as a common cause of community-acquired pneumoniaLisa Valdivia, David Nix, Mark Wright, et al.
European Journal of Gastroenterology & Hepatology|February 17, 2012
Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosisSudeep Tanwar, Mark Wright, Graham R Foster, et al.
Physiological Reports|March 25, 2020
Application of the optimized carbon monoxide rebreathing method for the measurement of total haemoglobin mass in chronic liver diseaseJames O M Plumb, James M Otto, Shriya B Kumar, et al.
Journal of Clinical Epidemiology|January 24, 2006
Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitmentMichael J Sweeting, Daniela De Angelis, Keith R Neal, et al.
Frontline Gastroenterology|March 15, 2024
Developing a generic business case for an advanced chronic liver disease support serviceMark Wright, Sarah Willmore, Sumita Verma, et al.
Pageof 13

Showing results (81-90 of 129) with videos related to

Sort By:
Pageof 13
The American Journal of Gastroenterology|December 24, 2014
Metabolic phenotyping for enhanced mechanistic stratification of chronic hepatitis C-induced liver fibrosisCaroline J Sands, Indra N Guha, Michael Kyriakides, et al.
BMC Nephrology|May 21, 2021
Patient perspectives of target weight management and ultrafiltration in haemodialysis: a multi-center surveyDavid Keane, Megan Glyde, Indranil Dasgupta, et al.
BMJ Open|March 16, 2019
Validated methods to identify patients with asthma-COPD overlap in healthcare databases: a systematic review protocolJoseph Emil Amegadzie, Oluwatosin Badejo, John-Michael Gamble, et al.
International Journal of Molecular Sciences|November 9, 2024
Adjuvanted Modified Bacterial Antigens for Single-Dose VaccinesRoberta Di Benedetto, Luisa Massai, Mark Wright, et al.
Plos One|October 3, 2013
Ascitic microbiota composition is correlated with clinical severity in cirrhosis with portal hypertensionGeraint B Rogers, Christopher J van der Gast, Kenneth D Bruce, et al.
Emerging Infectious Diseases|May 19, 2006
Coccidioidomycosis as a common cause of community-acquired pneumoniaLisa Valdivia, David Nix, Mark Wright, et al.
European Journal of Gastroenterology & Hepatology|February 17, 2012
Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosisSudeep Tanwar, Mark Wright, Graham R Foster, et al.
Physiological Reports|March 25, 2020
Application of the optimized carbon monoxide rebreathing method for the measurement of total haemoglobin mass in chronic liver diseaseJames O M Plumb, James M Otto, Shriya B Kumar, et al.
Journal of Clinical Epidemiology|January 24, 2006
Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitmentMichael J Sweeting, Daniela De Angelis, Keith R Neal, et al.
Frontline Gastroenterology|March 15, 2024
Developing a generic business case for an advanced chronic liver disease support serviceMark Wright, Sarah Willmore, Sumita Verma, et al.
Pageof 13